Summary.-The concentration of the common a subunit of the glycoprotein hormones was high in the serum of 21/56 (38o%) of premenopausal patients and 22/106 (21 %) of postmenopausal patients with primary breast cancer, at the time of presentation. 7/59 (12%) of patients with benign disease also had high a subunit levels. Tumour cytosol oestrogen and progesterone receptor status was determined in 80% of the patients with cancer, and there was a trend towards higher a levels in patients without receptors, but this was not statistically significant. In the premenopausal patients with cancer there was a significant correlation between a subunit level and disease stage, R=0.47, P=0.0001, but not in the postmenopausal patients. In view of the correlation with disease stage, high levels of a subunit in premenopausal patients with breast cancer at presentation with the primary tumour may indicate poor prognosis.
THE COMMON ax subunit of the glycoprotein hormones (thyroid-stimulating hormone-TSH; follicle-stimulating hormone FSH; luteinizing hormone LH, and chorionic gonadotrophin hCG) has been found in breast-tumour cultures (Cove et al., 1979; Miller et al., unpubl.) . Immunoperoxidase staining has demonstrated the presence of oa subunit in histological specimens of breast carcinomas, and lymph-node metastases found at the initial operation are said to be common in patients with ay subunit-positive primary tumours (Walker, 1978) .
Increased concentrations of oa subunit have been found in the serum of persons with various benign and malignant conditions (Dosogne-Guerin et al., 1978; Braunstein et al., 1979) and we report here a study of serum a subunit levels in a large consecutive series of patients presenting with primary breast cancer, and compare them with oa subunit levels in patients with benign breast disease and a normal control population. In order to define the importance of serum oa subunit measurement in our breast-cancer patients, we have correlated oa levels with the tumour hormonereceptor status and disease stage at removal of the primary tumour, both factors known to influence patient survival (Say & Donegan, 1974; Hahnel et al., 1979 Controls.-112 female blood donors and healthy female hospital personnel served as controls. There were 56 premenopausal women, median age 25 (range 17-51) and 56 postmenopausal women, median age 54 (range 47-74). In a further 8 premenopausal controls, blood was taken several days before and several days after ovulation, ovulation being confirmed by LH and FSH peaks.
In all patients histological proof of the diagnosis was obtained. Blood was taken from 147 of the cancer group and 17 of the benign group before surgical removal of the tumour. In the remaining patients blood was taken within 24 h of surgery. Serum was stored at -20°C before measurement, by radioimmunoassay, of of subunit concentration (ng/ml). Postmenopausal women were defined as having amenorrhoea for 6 months and serum FSH levels > 20 mu/l.
Serum ax subunit assay
This was performed by double antibody radioimmunoassay using o-TSH standard and its antibody as previously described (MacFarlane et at., 1979). The lower limit of detection was 0 5 ng/ml of serum.
Breast cancer hormone receptor assay
In 40 of the premenopausal patients with cancer the cytoplasmic oestrogen receptor activity (REc) and the cytoplasmic progesterone receptor activity (RPc) were determined in the primary tumours. In 27 of these 40 premenopausal patients, the nuclear oestrogen receptor activity (REN) was also estimated. In the postmenopausal patients with cancer, 91 had the REC estimated, 89 had the RPC estimated, and 41 had the REN activity estimated. The hormone receptors were estimated by previously published methods: REC and RPc (Barnes et al., 1977) ; REN (Barnes et al., 1979) .
Disease staging in breast-cancer patients Tumours were grouped into stages (I-IV) taking into account the tumour size and the axillary-node status, the latter being confirmed by histological examination (Harmer, 1978) .
RESULTS
The of subunit concentrations in the 3 groups (cancer, benign and controls) are displayed in Fig. 1 (premenopausal) and Fig. 2 (postmenopausal) . In the premenopausal women, median oc subunit levels and ranges were as follows: breast cancer 1-05 ng/ml (0.4-200); benign disease 0 95 ng/ml (0.4-22) and controls 0-8 ng/ml (0.4-4 3). Taking 2-3 ng/ml as the upper limit of normal (defined as the 95% confidence limit in the premenopausal controls), there were 21/56 (38%) cancer patients, 6/46 (13%) benign patients and 2/56 normals with high cx levels. In the premenopausal patients with breast cancer, ox subunit levels were statistically significantly higher than in the premenopausal controls (P = 0 037; Mann-Whitney U test). There was no statistically significant difference in ox level between the premenpausal patients with benign breast disease and the premenopausal controls (----upper 95% limit of normal in controls.) Cancer vs control, P = 0-037.
In 8 premenopausal controls, serial measurement of of subunit at ovulation revealed acute elevations of as subunit. In 3 patients the peak ox subunit level exceeded 5 ng/ml. :~--i-n---_ In the postmenopausal women median o subunit levels and ranges were as follows: breast cancer 5-7 ng/ml (0-4-24); benign disease 4 ng/ml (1-9.6) and controls 4-4 ng/ml (1-4-10). Taking 9-5 ng/ml as the upper limit of normal (defined as the 95% confidence limit in the postmenopausal controls) there were 22/106 (21%) cancer patients, 1/13 benign patients and 2/56 controls with high a subunit levels. Comparing the 3 postmenopausal groups (cancer, benign and controls) there were no statistically significant differences in cx levels (P > 0-18). (Dosogne-Guerin et al., 1978) and 10/104 (10%) (Cove et al., 1979) with high ax levels. The differences in incidence of high a levels in these studies may in part be due to different definitions of the normal range.
Comparing the premenopausal cancer patients with the premenopausal control population we found that ax subunit levels were significantly higher in the cancer group. The ages of the premenopausal patients with cancer were higher than those of the premenopausal controls, but this was not the cause of the increased oasubunit levels in the cancer group. There was no correlation between ax subunit levels and age in the premenopausal patients with cancer (r = 0'06, P > 0 5) or in the premenopausal controls (r = 0a 12, P > 0.2). There was no significant difference in a level on comparing the postmenopausal cancer patients with the postmenopausal patients with benign disease and the postmenopausal controls. In a previous study of patients with metastatic melanoma we also found that oa subunit levels were more frequently high in premenopausal than in postmenopausal patients (MacFarlane et al., 1979) . It is possible that the lack of significant difference in oa level between the postmenopausal patients with breast cancer and the postmenopausal controls may reflect the higher normal base line for Oa subunit than in premenopausal individuals.
Apart from malignancy, several other clinical conditions have been shown to be associated with increased serum oa subunit levels. Excessive pituitary secretion of oa subunit is found in primary hypothyroidism (Kourides et al., 1975) and occasionally patients with pituitary tumours have increased oa subunit levels (MacFarlane et al., 1980b) . In pregnancy, cx subunit is secreted by the placenta (Vaitukaitis et al., 1976) and patients with renal failure also have high levels (tiagen et al., 1976) . None of the subjects in this study was pregnant, no other disease was evident and thyroid-function tests revealed no trend towards hypothyroidism (MacFarlane et al., 1980a) . Our finding of acute increases in of subunit levels, presumably originating from the pituitary, at the time of ovulation agrees with another recent study (Rosenberg & Bulat, 1979) . In 5 of our 21 premenopausal patients with cancer who had high ax levels, LH and FSH concentrations measured in the same serum sample were also high, suggesting recent ovulation. Therefore the pituitary may have contributed to the high of concentration in some of these premenopausal patients.
It is of interest that 6/46 premenopausal patients with benign disease had high of levels and there was no significant difference in ox concentrations between the premenopausal patients with benign disease and those with cancer. Only one of these 6 benign patients had gonadotrophin levels compatible with recent ovulation. Recently other grouips have also documented increases in a levels in benign as well as malignant conditions (Dosogne-Guerin et al., 1978; Braunstein et al., 1979) . These observations are at variance with results of a study of patients with pancreatic islet-cell tumours, in which serum of subunit was high only in malignant tumours, and normal in benign cases (Kahn et al., 1977) .
Patients with REc+ breast ttimours liave a significantly better survival than those who are REC- (Hcihnel et al., 1979) and patients with advanced breast cancer and REC± tumours respond better to hormonal therapy than those who are negative (Barnes et al., 1977 (Lippman et al., 1978; Kiang et al., 1978) . In this studv there was no statistical correlation between of subunit levels and the presence or absence of hormone receptors, either individuallv or in combination though there was a definite trend towards higher a levels in those pre-and postmenopausal patients who were REC-and RPC-.
In the premenopausal patients of levels were higher in REN-patients than in REN+ patients.
In premenopausal patients with cancer a positive correlation between of subunit levels and disease stage was found, but not, however, in the postmenopausal group. More advanced disease stage at presentation is associated with a reduced survival of patients with breast cancer (Say et al., 1974) , and therefore the high levels of o subunit in premenopausal patients at presentation with breast cancer may indicate a worse prognosis.
In a study of patients with metastatic melanoma, high pretreatment of subunit levels in premenopausal women were associated with a reduced survival and failure to respond to chemo-immunotherapy (MacFarlane et al., 1979) . As all the patients with melanoma were in the same stage grouping, increased cx subunit levels suggested a more malignant, uinresponsive type of melanoma. However, in the premenopausal patients with breast cancer studied here, we are unable to assume that high cx levels represent a more malignant tumour; they may merely reflect a greater tumour burden.
The use of x subunit as a tumour marker appears limited. The increases in ax concentrations found in the patients with breast cancer were usually moderate and there was considerable overlap in serum ax levels between the 3 groups (cancer, benign and controls 
